<div class="tables frame-topbot rowsep-0 colsep-0" id="tbl1">
<div class="captions"><span id="cecap50"><p id="spara90"><span class="label">Table</span>. Baseline characteristics by study and blood pressure intervention in participants with baseline eGFR 60 mL/min per 1·73 m<sup>2</sup> or higher</p></span></div>
<div class="groups"><table>
<thead>
<tr class="valign-top">
<th scope="col"></th>
<th scope="col" class="align-left rowsep-1" colspan="2"><strong>ACCORD trial</strong></th>
<th scope="col" class="align-left rowsep-1" colspan="2"><strong>SPRINT</strong></th>
</tr>
<tr class="valign-top rowsep-1">
<th scope="col"></th>
<th scope="col" class="align-left">Standard (n=2162)</th>
<th scope="col" class="align-left">Intensive (n=2149)</th>
<th scope="col" class="align-left">Standard (n=3367)</th>
<th scope="col" class="align-left">Intensive (n=3348)</th>
</tr>
</thead>
<tbody>
<tr class="valign-top">
<td class="align-left">Age (years)</td>
<td class="align-left">61·7 (57·4–66·7)</td>
<td class="align-left">61·4 (57·4–66·4)</td>
<td class="align-left">65 (60–73)</td>
<td class="align-left">65 (59–73)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Female sex</td>
<td class="align-left">1007 (47%)</td>
<td class="align-left">992 (46%)</td>
<td class="align-left">1127 (33%)</td>
<td class="align-left">1147 (34%)</td>
</tr>
<tr class="valign-top">
<td class="align-left">White ethnic origin</td>
<td class="align-left">1224 (57%)</td>
<td class="align-left">1280 (60%)</td>
<td class="align-left">1808 (54%)</td>
<td class="align-left">1813 (54%)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Never smoked</td>
<td class="align-left">938 (43%)</td>
<td class="align-left">925 (43%)</td>
<td class="align-left">1471 (44%)</td>
<td class="align-left">1444 (43%)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Clinical atherosclerotic disease<a name="btbl1fn1" href="#tbl1fn1" class="workspace-trigger"><sup>*</sup></a>
</td>
<td class="align-left">707 (33%)</td>
<td class="align-left">716 (33%)</td>
<td class="align-left">503 (15%)</td>
<td class="align-left">503 (15%)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Antihypertensive agents (n per patient)</td>
<td class="align-left">1·6 (1·1)</td>
<td class="align-left">1·7 (1·1)</td>
<td class="align-left">1·7 (1·0)</td>
<td class="align-left">1·7 (1·0)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Systolic blood pressure (mm Hg)</td>
<td class="align-left">139 (15)</td>
<td class="align-left">139 (16)</td>
<td class="align-left">140 (15)</td>
<td class="align-left">140 (16)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Diastolic blood pressure (mm Hg)</td>
<td class="align-left">76 (10)</td>
<td class="align-left">76 (10)</td>
<td class="align-left">79 (12)</td>
<td class="align-left">79 (12)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Duration of diabetes (years)</td>
<td class="align-left">11 (8)</td>
<td class="align-left">11 (8)</td>
<td class="align-left">N/A</td>
<td class="align-left">N/A</td>
</tr>
<tr class="valign-top">
<td class="align-left">HbA<sub>1c</sub> (%)</td>
<td class="align-left">8·3 (1·0)</td>
<td class="align-left">8·4 (1·0)</td>
<td class="align-left">N/R</td>
<td class="align-left">N/R</td>
</tr>
<tr class="valign-top">
<td class="align-left">HbA<sub>1c</sub> (mmol/mol)</td>
<td class="align-left">67 (11)</td>
<td class="align-left">68 (11)</td>
<td class="align-left">N/R</td>
<td class="align-left">N/R</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Fasting plasma glucose (mmol/L)</td>
<td class="align-left">9·6 (3·0)</td>
<td class="align-left">9·8 (3·0)</td>
<td class="align-left">5·5 (0·8)<a name="btbl1fn2" href="#tbl1fn2" class="workspace-trigger"><sup>†</sup></a>
</td>
<td class="align-left">5·5 (0·8)<a name="btbl1fn2" href="#tbl1fn2" class="workspace-trigger"><sup>†</sup></a>
</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">Body-mass index (kg/m<sup>2</sup>)</td>
<td class="align-left">32·1 (5·3)</td>
<td class="align-left">32·1 (5·6)</td>
<td class="align-left">30·0 (5·7)</td>
<td class="align-left">30·1 (5·8)</td>
</tr>
<tr class="valign-bottom">
<td class="align-left">eGFR<a name="btbl1fn3" href="#tbl1fn3" class="workspace-trigger"><sup>‡</sup></a> (mL/min per 1·73 m<sup>2</sup>)</td>
<td class="align-left">94·0 (20·8)</td>
<td class="align-left">94·2 (20·7)</td>
<td class="align-left">81·1 (15·5)</td>
<td class="align-left">81·3 (15·5)</td>
</tr>
<tr class="valign-top">
<td class="align-left">Urinary ACR (mg/mmol)</td>
<td class="align-left">1·6 (0·8–5·1)</td>
<td class="align-left">1·7 (0·8–5·0)</td>
<td class="align-left">1·0 (0·6–1·9)</td>
<td class="align-left">1·0 (0·6–1·9)</td>
</tr>
</tbody>
</table></div>
<p class="legend"></p>
<p id="spara100">Data are number of patients (%), mean (SD), or median (IQR). ACCORD=Action to Control <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/cardiovascular-risk" title="Learn more about Cardiovascular Risk from ScienceDirect's AI-generated Topic Pages">Cardiovascular Risk</a><span><span> in Diabetes. ACR=albumin:creatinine ratio. eGFR=estimated <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/glomerular-filtration-rate" title="Learn more about Glomerular Filtration Rate from ScienceDirect's AI-generated Topic Pages">glomerular filtration rate</a>. MDRD=Modification of Diet in </span><a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/nephropathy" title="Learn more about Nephropathy from ScienceDirect's AI-generated Topic Pages">Renal Disease</a><span>. N/A=not applicable. N/R=not reported. SPRINT=Systolic Blood Pressure <a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/intervention-trial" title="Learn more about Intervention Trial from ScienceDirect's AI-generated Topic Pages">Intervention Trial</a>.</span></span></p>
<p></p>
<dl class="footnotes">
<dt id="tbl1fn1">*</dt>
<dd><p id="cenpara10">Defined
 in the ACCORD trial as one or more of myocardial infarction, stroke, 
angina, coronary-artery bypass graft, percutaneous transluminal coronary
 intervention, or other revascularisation procedure. Defined in SPRINT 
as one or more of myocardial infarction, acute coronary syndrome, 
coronary revascularisation, carotid revascularisation, peripheral 
arterial disease with revascularisation, greater than 50% stenosis of 
coronary, carotid, or lower extremity artery, or abdominal aortic 
aneurysm 5 mm or larger.</p></dd>
<dt id="tbl1fn2">†</dt>
<dd><p id="cenpara20">113
 participants assigned the standard intervention and 112 allocated the 
intensive intervention had a fasting plasma glucose greater than 6·9 
mmol/L at baseline.</p></dd>
<dt id="tbl1fn3">‡</dt>
<dd><p id="cenpara30">Estimated by four-variable MDRD equation.</p></dd>
</dl>
</div>